{"component": "definition", "props": {"groups": [{"size": 139, "snippet": "means a human clinical trial conducted on study subjects with the disease or condition being studied for the principal purpose of achieving a preliminary determination of efficacy or appropriate dosage ranges, as further described in 21 C.F.R. \u00a7312.21(b) (including any such clinical study in any country other than the United States).", "snippet_links": [{"key": "human-clinical-trial", "type": "definition", "offset": [8, 28]}, {"key": "study-subjects", "type": "clause", "offset": [42, 56]}, {"key": "purpose-of", "type": "clause", "offset": [119, 129]}, {"key": "determination-of", "type": "clause", "offset": [154, 170]}, {"key": "clinical-study", "type": "definition", "offset": [275, 289]}, {"key": "the-united-states", "type": "definition", "offset": [316, 333]}], "samples": [{"hash": "ldamEC5xgC2", "uri": "/contracts/ldamEC5xgC2#phase-2-trial", "label": "Option and License Agreement (Curis Inc)", "score": 31.2121829987, "published": true}, {"hash": "aOHT56obAEQ", "uri": "/contracts/aOHT56obAEQ#phase-2-trial", "label": "Research Funding and Option Agreement (aTYR PHARMA INC)", "score": 26.2594108582, "published": true}, {"hash": "iNLFg1Ifybz", "uri": "/contracts/iNLFg1Ifybz#phase-2-trial", "label": "Research Funding and Option Agreement (aTYR PHARMA INC)", "score": 26.0869274139, "published": true}], "hash": "38b93535d779aba9cd6cfac6e32ec98d", "id": 1}, {"size": 30, "snippet": "means a human clinical trial that would satisfy the requirements for a Phase 2 study as defined in 21 CFR \u00a7 312.21(b) (or any amended or successor regulations), regardless of where such clinical trial is conducted.", "snippet_links": [{"key": "human-clinical-trial", "type": "definition", "offset": [8, 28]}, {"key": "requirements-for", "type": "clause", "offset": [52, 68]}, {"key": "phase-2-study", "type": "definition", "offset": [71, 84]}], "samples": [{"hash": "dlxPRls70rb", "uri": "/contracts/dlxPRls70rb#phase-2-trial", "label": "Asset Purchase Agreement (Equillium, Inc.)", "score": 34.22108078, "published": true}, {"hash": "4LpIQcwPwBY", "uri": "/contracts/4LpIQcwPwBY#phase-2-trial", "label": "Collaboration and License Agreement (Roivant Sciences Ltd.)", "score": 32.364818573, "published": true}, {"hash": "cflzw3hzEOg", "uri": "/contracts/cflzw3hzEOg#phase-2-trial", "label": "Collaboration and License Agreement (Cidara Therapeutics, Inc.)", "score": 30.8507862091, "published": true}], "hash": "2db2503b848268f922f7595d9b9730d8", "id": 2}, {"size": 11, "snippet": "means a human clinical trial of a Product in any country that satisfies the requirements of 21 C.F.R. \u00a7 312.21(b) or its foreign equivalent.", "snippet_links": [{"key": "human-clinical-trial", "type": "definition", "offset": [8, 28]}, {"key": "the-requirements", "type": "clause", "offset": [72, 88]}, {"key": "foreign-equivalent", "type": "definition", "offset": [121, 139]}], "samples": [{"hash": "a8U257pkrMy", "uri": "/contracts/a8U257pkrMy#phase-2-trial", "label": "License Agreement (Bluebird Bio, Inc.)", "score": 30.1389465332, "published": true}, {"hash": "gI8KVNH2PdT", "uri": "http://archive.fast-edgar.com//20190221/AEAIM22CZ222QTB4222N2ZZ2I6GHZY22Z2B2/", "label": "archive.fast-edgar.com", "score": 8.1704311371, "published": false}], "hash": "7dd8830ea90fd203dd822064127d532d", "id": 3}, {"size": 7, "snippet": "means a human clinical trial of a Product in any country that would satisfy the requirements of 21 C.F.R. \u00a7 312.21(b). For clarity, a trial called a Phase 1/2 or Phase 1b/2 trial shall be considered a Phase 2 trial if it satisfies the requirements of 21 C.F.R. \u00a7 312.21(b).", "snippet_links": [{"key": "human-clinical-trial", "type": "definition", "offset": [8, 28]}, {"key": "the-requirements", "type": "clause", "offset": [76, 92]}, {"key": "for-clarity", "type": "clause", "offset": [119, 130]}, {"key": "a-phase", "type": "clause", "offset": [147, 154]}], "samples": [{"hash": "3RPQeY6TZ8v", "uri": "/contracts/3RPQeY6TZ8v#phase-2-trial", "label": "Research Collaboration and License Agreement", "score": 31.3408622742, "published": true}, {"hash": "jAiDTxdVi4M", "uri": "/contracts/jAiDTxdVi4M#phase-2-trial", "label": "Research Collaboration and License Agreement (Five Prime Therapeutics Inc)", "score": 25.6488704681, "published": true}, {"hash": "454oKoCKws0", "uri": "/contracts/454oKoCKws0#phase-2-trial", "label": "Research Collaboration and License Agreement (Five Prime Therapeutics Inc)", "score": 25.3586578369, "published": true}], "hash": "e5a578332d924f9c24ba57ce3629a300", "id": 4}, {"size": 7, "snippet": "means a human clinical trial of an Agreement Product, the principal purpose of which is to make a preliminary determination that such Agreement Product is safe for its intended use and to obtain sufficient information about such Agreement Product\u2019s efficacy to permit the design of further clinical trials, and generally consistent with 21 CFR \u00a7 312.21(b), as amended (or its successor regulation).", "snippet_links": [{"key": "human-clinical-trial", "type": "definition", "offset": [8, 28]}, {"key": "agreement-product", "type": "definition", "offset": [35, 52]}, {"key": "purpose-of", "type": "clause", "offset": [68, 78]}, {"key": "preliminary-determination", "type": "definition", "offset": [98, 123]}, {"key": "intended-use", "type": "clause", "offset": [168, 180]}, {"key": "sufficient-information", "type": "definition", "offset": [195, 217]}, {"key": "the-design", "type": "clause", "offset": [268, 278]}, {"key": "clinical-trials", "type": "definition", "offset": [290, 305]}, {"key": "consistent-with", "type": "definition", "offset": [321, 336]}, {"key": "as-amended", "type": "definition", "offset": [357, 367]}], "samples": [{"hash": "eqnZ9J3EYT3", "uri": "/contracts/eqnZ9J3EYT3#phase-2-trial", "label": "License Agreement", "score": 31.3408622742, "published": true}, {"hash": "jkW1qUkbg5", "uri": "/contracts/jkW1qUkbg5#phase-2-trial", "label": "License Agreement (Exelixis Inc)", "score": 21.0, "published": true}], "hash": "09bc47161d9ba8441f2397c4daee901f", "id": 5}, {"size": 6, "snippet": "means a human clinical trial of a Product, the principal purpose of which is a determination of preliminary short-term safety and efficacy in the target patient population, as described in 21 C.F.R. 312.21(b) for the United States, or a similar clinical study prescribed by the Regulatory Authorities in a foreign country.", "snippet_links": [{"key": "human-clinical-trial", "type": "definition", "offset": [8, 28]}, {"key": "purpose-of", "type": "clause", "offset": [57, 67]}, {"key": "determination-of", "type": "clause", "offset": [79, 95]}, {"key": "safety-and-efficacy", "type": "clause", "offset": [119, 138]}, {"key": "the-target", "type": "clause", "offset": [142, 152]}, {"key": "patient-population", "type": "definition", "offset": [153, 171]}, {"key": "for-the-united-states", "type": "clause", "offset": [209, 230]}, {"key": "clinical-study", "type": "definition", "offset": [245, 259]}, {"key": "regulatory-authorities", "type": "clause", "offset": [278, 300]}, {"key": "in-a-foreign-country", "type": "clause", "offset": [301, 321]}], "samples": [{"hash": "dD10JSz0mAA", "uri": "/contracts/dD10JSz0mAA#phase-2-trial", "label": "Collaboration and License Agreement (Regulus Therapeutics Inc.)", "score": 25.1587944031, "published": true}, {"hash": "9JdAev0aghH", "uri": "/contracts/9JdAev0aghH#phase-2-trial", "label": "Collaboration and License Agreement (Regulus Therapeutics Inc.)", "score": 23.6255989075, "published": true}, {"hash": "bUYuvPY7hwz", "uri": "/contracts/bUYuvPY7hwz#phase-2-trial", "label": "Collaboration and License Agreement (Isis Pharmaceuticals Inc)", "score": 21.6023273468, "published": true}], "hash": "d06e3d8d02cd3540d4ec1e7d545fd89f", "id": 6}, {"size": 6, "snippet": "means, with respect to a drug candidate, that portion of the clinical development program which provides for clinical trials of a drug candidate in patients for the purpose of generating at least initial evidence related to the safe and effective dose range in the proposed therapeutic indication, as more fully described in 21 C.F.R. \u00a7 312.21(b), or its successor regulation, or the equivalent in any foreign country.", "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [7, 22]}, {"key": "drug-candidate", "type": "definition", "offset": [25, 39]}, {"key": "clinical-development-program", "type": "definition", "offset": [61, 89]}, {"key": "clinical-trials", "type": "definition", "offset": [109, 124]}, {"key": "for-the-purpose-of", "type": "definition", "offset": [157, 175]}, {"key": "related-to", "type": "definition", "offset": [213, 223]}, {"key": "the-proposed", "type": "clause", "offset": [261, 273]}, {"key": "therapeutic-indication", "type": "definition", "offset": [274, 296]}, {"key": "foreign-country", "type": "definition", "offset": [402, 417]}], "samples": [{"hash": "eV585P4oeeN", "uri": "/contracts/eV585P4oeeN#phase-2-trial", "label": "Collaboration Agreement (Receptos, Inc.)", "score": 24.2881584167, "published": true}, {"hash": "2BjuBpAfMGG", "uri": "/contracts/2BjuBpAfMGG#phase-2-trial", "label": "Collaboration Agreement (Receptos, Inc.)", "score": 24.2553043365, "published": true}, {"hash": "id2SSWDOKXS", "uri": "/contracts/id2SSWDOKXS#phase-2-trial", "label": "Collaboration Agreement (Receptos, Inc.)", "score": 24.1184120178, "published": true}], "hash": "e2cceba00c6bc181e576b940a8739aca", "id": 7}, {"size": 5, "snippet": "means a clinical trial of a pharmaceutical product: (a) with the endpoint of evaluating its effectiveness for a particular indication or indications, its short term tolerance and safety, as well as its pharmacokinetic and pharmacodynamic data in patients with the indications under study and is not intended to be pivotal to support marketing approval for such product; or (b) that meets the definition in 21 C.F.R. \u00a7312.21(b) or any of its foreign equivalents.", "snippet_links": [{"key": "clinical-trial", "type": "definition", "offset": [8, 22]}, {"key": "pharmaceutical-product", "type": "definition", "offset": [28, 50]}, {"key": "short-term", "type": "clause", "offset": [154, 164]}, {"key": "and-safety", "type": "clause", "offset": [175, 185]}, {"key": "marketing-approval", "type": "definition", "offset": [333, 351]}, {"key": "the-definition", "type": "definition", "offset": [388, 402]}], "samples": [{"hash": "3fdZ2B8pCgq", "uri": "/contracts/3fdZ2B8pCgq#phase-2-trial", "label": "License Agreement (Immune Design Corp.)", "score": 28.1676940918, "published": true}], "hash": "fb8832f9c181bbd714c396dc028e3b03", "id": 8}, {"size": 4, "snippet": "means, as to a specific pharmaceutical product, a well conducted and lawful study, conducted anywhere in the world in diseased humans, of the feasibility, safety, dose ranging and efficacy of such product, that is prospectively designed to generate sufficient data (if successful) to commence a Phase 3 Trial (or foreign equivalent) of such product, as further defined in 21 C.F.R. 312.21(b), as amended from time to time, or the corresponding regulation in jurisdictions other than the United States. For the avoidance of doubt, a Phase 2 Trial requires enrollment of patients with the applicable disease or condition and is aimed to provide a measure of efficacy in addition to short-term tolerability. A Phase 2 Trial shall be deemed initiated upon the enrollment of the first patient.", "snippet_links": [{"key": "pharmaceutical-product", "type": "definition", "offset": [24, 46]}, {"key": "the-world", "type": "definition", "offset": [105, 114]}, {"key": "to-generate", "type": "definition", "offset": [237, 248]}, {"key": "phase-3-trial", "type": "definition", "offset": [295, 308]}, {"key": "foreign-equivalent", "type": "definition", "offset": [313, 331]}, {"key": "further-defined", "type": "clause", "offset": [353, 368]}, {"key": "as-amended", "type": "definition", "offset": [393, 403]}, {"key": "from-time-to-time", "type": "clause", "offset": [404, 421]}, {"key": "the-united-states", "type": "definition", "offset": [483, 500]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [502, 528]}, {"key": "the-applicable", "type": "clause", "offset": [583, 597]}, {"key": "provide-a", "type": "definition", "offset": [635, 644]}, {"key": "in-addition-to", "type": "clause", "offset": [665, 679]}], "samples": [{"hash": "iXFlrYpX8ED", "uri": "/contracts/iXFlrYpX8ED#phase-2-trial", "label": "Collaboration Agreement (Biotech Spinco, Inc.)", "score": 21.0, "published": true}, {"hash": "aCHiyqOrIMW", "uri": "/contracts/aCHiyqOrIMW#phase-2-trial", "label": "Collaboration Agreement (Facet Biotech Corp)", "score": 21.0, "published": true}, {"hash": "8eDFan9vtXQ", "uri": "/contracts/8eDFan9vtXQ#phase-2-trial", "label": "Collaboration Agreement (Protein Design Labs Inc/De)", "score": 21.0, "published": true}], "hash": "b910000972a08604df43fc8730f95af2", "id": 9}, {"size": 3, "snippet": "means a human clinical trial that would satisfy the requirements for a Phase 2 study as defined in 21 CFR \u00a7 312.21(b), or any foreign equivalent thereof.", "snippet_links": [{"key": "human-clinical-trial", "type": "definition", "offset": [8, 28]}, {"key": "requirements-for", "type": "clause", "offset": [52, 68]}, {"key": "phase-2-study", "type": "definition", "offset": [71, 84]}, {"key": "foreign-equivalent", "type": "definition", "offset": [126, 144]}], "samples": [{"hash": "9SpRRGNX27W", "uri": "/contracts/9SpRRGNX27W#phase-2-trial", "label": "Research, License, and Collaboration Agreement (Dyadic International Inc)", "score": 32.9589309692, "published": true}, {"hash": "dHT6Tcb0GlJ", "uri": "/contracts/dHT6Tcb0GlJ#phase-2-trial", "label": "Exclusive License and Collaboration Agreement (Cidara Therapeutics, Inc.)", "score": 32.3620796204, "published": true}, {"hash": "6B9cAy01AVw", "uri": "https://ir.cidara.com/static-files/66080cc4-4c7c-4a5f-8cd9-ce7ac4794c37", "label": "ir.cidara.com", "score": 10.6810407639, "published": false}], "hash": "2e3d3de61edc2104739a0169382aa353", "id": 10}], "next_curs": "CloSVGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjYLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIWcGhhc2UtMi10cmlhbCMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"size": 258, "title": "Phase 2 Trial", "snippet": "means a human clinical trial conducted on study subjects with the disease or condition being studied for the principal purpose of achieving a preliminary determination of efficacy or appropriate dosage ranges, as further described in 21 C.F.R. \u00a7312.21(b) (including any such clinical study in any country other than the United States).", "id": "phase-2-trial", "examples": ["If the Milestone Event for Initiation of a <strong>Phase 2 Trial</strong> for a Licensed Product set forth in Section 7.3.1(a) or Section 7.3.1(b) has failed to be achieved and BMS (or any of its Affiliates or Sublicensees) achieves the Initiation of a Registrational Trial, then such Milestone Event shall be deemed achieved and BMS shall pay to Avidity the Milestone Payment corresponding to Initiation of the <strong>Phase 2 Trial</strong> for a Licensed Product set forth in Section 7.3.1(a) or Section 7.3.1(b), as applicable."], "related": [["phase-3-trial", "Phase 3 Trial", "Phase 3 Trial"], ["phase-1-trial", "Phase 1 Trial", "Phase 1 Trial"], ["phase-ii-trial", "Phase II Trial", "Phase II Trial"], ["phase-i-trial", "Phase I Trial", "Phase I Trial"], ["phase-iii-trial", "Phase III Trial", "Phase III Trial"]], "related_snippets": [], "updated": "2026-05-28T05:54:56+00:00"}, "json": true, "cursor": ""}}